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Abstract
Analysis of volatile organic compounds (VOCs) in exhaled breath is non-invasive 
method and appears as a promising tool for metabolic monitoring. Diabetes is a 
complex syndrome, metabolic diseases that is characterized by hyperglycemia 
associated with major changes in lipids and proteins. The pathophysiology of the 
link between diabetes, hypertension, inflammatory syndrome and oxidative stress 
is complex. We conducted a study and applied quantitative analysis of exhaled eth-
ylene and ammonia in patients with type 2 diabetes mellitus (T2DM) and a healthy 
control group. For breath gas analysis, a very sensitive CO2 laser photoacoustic 
spectroscopy (CO2LPAS) was applied. The concentration of exhaled VOCs differed 
between T2DM patients and healthy group, in particular, T2DM patients exhaled 
significantly higher amounts of ethylene and ammonia compared to healthy con-
trol group. The data obtained by the CO2LPAS system revealing that the increased 
breath VOCs has a close relationship with high glucose levels and with healthy 
complications.
Keywords: type 2 diabetes, exhaled breath, volatile organic compounds, ethylene, 
ammonia, CO2 laser photoacoustic spectroscopy
1. Introduction
The analysis of volatile organic compounds (VOCs) represents a rapid and 
non-invasive method of early diagnosis. Some of the detected VOCs can be used as 
biomarkers for certain diseases or can reflect the metabolic profile of an organism 
and are presented in the exhaled breath, skin secretions, saliva, blood, urine and 
feces [1]. Breath analysis is considered to be a promising tool for noninvasive analysis 
of biochemical processes in the human body [2–5]. Exhaled breath contains both 
exogenous VOCs that come from environmental exposures as the ingestion of food, 
smoking cigarettes or/and air pollution, or endogenous VOCs that are produced by 
biological processes in the human body like oxidative stress (OS), inflammation, 
infectious disease. Breath analysis is currently used in the diagnosis of different 
pathologies, including gastrointestinal and liver disease, renal failure, lung disor-
ders, cancer, and diabetes [6–8].
Diabetes Mellitus (DM) affects millions of people worldwide, and the inci-
dence is increasing every year. Diabetes is a chronic condition characterized by 
hyperglycemia caused by a defect in insulin secretion or insulin action. Diabetes is 
a heterogeneous syndrome, characterized by a complex disorder in the regulation 
of the body’s energy metabolism, which affects the use of carbohydrates, lipids and 
proteins, as well as other metabolisms [1–3]. The most prevalent type of DM is: 
Type 2 Diabetes
2
type 2 diabetes mellitus (T2DM), type 1 diabetes mellitus (T1DM) and gestational 
diabetes mellitus (GDM). According to International Diabetes Federation (IDF) 
1 of 11 adults (20–79 years) have diabetes (463 million people), 1 in 2 adults with 
diabetes are undiagnosed (232 million people) and 2 in 3 people with diabetes lives 
in urban areas (310.3 million) [9, 10].
Individuals with T2DM presents increased risk for microvascular and macro-
vascular complications due to hyperglycemia. The complications related to diabetes 
are: eye disease (diabetic retinopathy), cardiovascular disease (one-third do half of 
all are diabetes related deaths), kidney disease, oral, nerve and/or vascular damage 
and diabetic foot complications (diabetic foot and lower limb complications affect 
between 40 and 60 million people with diabetes globally), diabetes-related com-
plications of pregnancy (approximately 20.4 million of live births were affected by 
hyperglycemia in pregnancy in 2019) [9–14].
Studies over time have shown that oxidative stress contributes to the develop-
ment and progression of diabetes, in T2DM particularly [15]. In diabetics, through 
hyperglycemia, hyperlipidemia, and hypertension is induced oxidative stress that 
affects multiple organs, leading to various complications including coronary artery 
disease, stroke, neuropathy, nephropathy, retinopathy [16, 17].
The aim of this chapter is showing the role of breath analysis in the evolution 
of type 2 diabetes mellitus by measuring ethylene and ammonia as oxidative stress 
breath biomarkers at T2DM and healthy subjects, using a CO2 laser photoacoustic 
spectroscopy (CO2LPAS) system. At the same time, it was determined the glycated 
hemoglobin HbA1c and blood glucose levels. Breath tests were compared between 
the two groups (healthy and with T2DM) to see if the breath analysis can discrimi-
nate between diabetic and healthy subjects, and if the breath tests are in accordance 
with blood tests.
2. Oxidative stress in diabetes mellitus
When the human’s cells are perturbed by nutritional imbalance, infections, 
bacteria, toxins or disease reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) are formed. ROS molecules are highly reactive and, the pathological 
consequence is damage to proteins, lipids and DNA [18, 19]. This oxidative damage 
may lead cell death and disease such as cancer or diabetes. Thus, oxidative stress 
may fi define as an imbalance between production of such reactive species and the 
body’s ability to detoxify.
Diabetic subjects tend to have an increase in ROS generation and a decrease in 
antioxidant defenses [18–24], in this case oxidative stress is a response to glucose 
and/or lipid overload. Thus, oxidative stress is involved in the occurrence of com-
plications in subjects with T2DM [20–24], and also affect the two major mecha-
nisms failing during diabetes: insulin resistance and insulin secretion [25–28].
According to Giugliano et al. patients with diabetes present a high level of 
oxidative stress leads to the appearance of atherosclerosis [29]. Also, according 
to Ceriello, hyperglycemia generates oxidative stress, which leads to endothelial 
dysfunction in blood vessels [30]. Atherosclerotic disease is the most important and 
frequent macrovascular complication in diabetics and it means the chronic inflam-
mation and injury to the arterial. Oxidized lipids accumulate in the endothelial wall 
of the arteries, and this accumulation can lead to acute vascular infarction [20].
The link between diabetes and oxidative stress was conducted by measuring 
certain biomarkers such as lipid peroxidation products, biomarker for protein oxi-
dation or DNA damage biomarker. These biomarkers are the result of free radical’s 
damage on lipids, proteins and DNA [18–20].
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Responsible for oxidative stress is the attack on proteins induce by the reaction 
between ROS and some amino acids [24]. Proteins are the principal target of ROS 
causing protein glycation and oxidative degeneration. Therefore, glycated hemoglo-
bin HbA1c measure the protein alteration and is considered as biomarker of oxida-
tive stress [31]. Ammonia is a biomarker of protein metabolism, and at subjects 
with T2DM, insulin deprivation is associated with an increase in amino acids and by 
an accelerated protein catabolism.
In diabetes the lipid profile is modified thus leading to the occurrence of lipid 
peroxidation. Another target of free radicals are the polyunsaturated fatty acids 
in cell membranes [32]. The end-products of LP that can be used to measure the 
effects of free radicals on lipids are malondialdehyde (MDA) measured in blood and 
ethylene as breath biomarker [33].
3. VOCs biomarkers in exhaled breath
3.1 Overview of breath analysis
Breath analysis can be considered as a potentially tool for the diagnosis and 
study of medical diseases. Respiratory analysis has been used in medicine since 
ancient times, from the time of Hippocrates (460–370 BC), when ancient Greek 
doctors assessing human health using human breath aroma [34–39]. The first 
breath analysis was conducted by Lavoisier in 1782, this showing that carbon 
dioxide from breathing is a product of combustion produced in the body [2, 38–40]. 
Respiratory studies continued later, when it was shown that human respiration 
contains VOCs, important in assessing human health [3–5]. The first invention 
that use gaseous compounds exhaled breath to assess human health was made in 
1931 by Dr. Rolla N. Harger. He invented the ‘drunkometer a breath-alcohol test, 
used to determine the alcohol concentration and has been widely used since 1938. 
An important step in breath analysis was conducted by Pauling et al. in 1971 when 
using a gas chromatograph were able to detect more than 200 VOCs in human 
breath [40]. Many studies on exhaled breath have been carried aiming to character-
ize these VOCs, and the studies carried out of Phillips estimated 1259 compounds in 
normal subjects in 1997 [41], and over 3000 compounds in 1999 [42]. The analysis 
of exhaled air is under investigation as a promising tool for express and noninvasive 
analysis of biochemical processes in the human body. The techniques currently used 
are promising to translate into clinics not for a specific disease diagnostic but more 
for providing information about biochemical processes that arise from underlying 
diseases. Nowadays, there are several commercially available devices for monitoring 
of breath biomarkers, such as 13C used to diagnose Helicobacter pylori [43], CH4 in 
breath accompanied by electrochemical sensors to detect H2 and O2 for diagnosis 
of gastrointestinal disorders [44], asthma detection by exhaled nitric oxide, breath 
alcohol testing [45], lung cancer detection [46], fructose malabsorption with 
hydrogen breath test, monitoring uptake of disinfection by-products following 
swimming [47] chronic kidney disease (CKD) and diabetes mellitus [48].
3.2 Exhaled breath
Human respiration is a gaseous mixture, and the main compounds are nitrogen, 
oxygen, carbon dioxide, inert gases, water vapor. In addition to these compounds 
that are found in high concentration in respiration, VOCs and inorganic molecules 
can also be found [49]. The presence of the latter in the composition of respiration 
depends on several external or internal factors. Thus, the composition of human 
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respiration is influenced both by exogenous compounds from exposure of the 
human body to various external environmental factors, and from endogenous 
compounds resulting from biological processes produced in the human body (in the 
lung tract, blood or peripheral tissues) [50].
Humans breath is a mixture of nitrogen, oxygen, carbon dioxide, inert gases, 
water vapor and thousands of VOCs traces and inorganic molecules [49]. The 
composition of breath contains exogenous compounds that originate from envi-
ronmental exposures, and endogenous compounds that are produced by biological 
processes in the human body (in the pulmonary tract, blood, or peripheral tissues) 
[50]. The complex matrix of breath varies from each person both quantitatively and 
qualitatively. The development of different methods for gas samples analysis has 
allowed the detection of gaseous compounds traces from respiration, and research 
has shown that the most common VOCs in human respiration are nitric oxide 
(10–50 ppb), 1–20 ppb), ammonia (0, 5–2 ppm), carbon monoxide (0–6 ppm), 
hydrogen sulfide (0–1.3 ppm), acetone (0.3–1 ppm), methane (2–10 ppm), pentane 
(0–10 ppb) etc. [51–56].
3.3 Breath biomarkers
Biomarkers are chemicals, usually VOCs, which indicate the normal or abnormal 
process that take place in the human body and can suggest the presence of a disease 
or a recent exposure to a drug or an environmental pollutant. The most important 
breath biomarkers are ammonia, acetone, isoprene, nitic oxide, hydrogen sulphide, 
methane, ethane and pentane [30–42, 51–58].
3.3.1 Ammonia
Ammonia (NH3) is very important for the human body and is involved in many 
physiological processes. The ammonia originates from the catabolism of the amino 
acids (which are produced mainly by degradation of proteins), can penetrate the 
blood-lungs and appears in the exhaled breath. Ammonia is absorbed into the por-
tal circulation, taken up by the liver and converted to urea by the urea cycle. Urea 
cycle is the metabolic pathway that converts urea nitrogen excretion from the body.
Ammonia (NH3) is highly toxic to humans, it is converted into urea which is 
non-toxic, highly soluble and easily excreted by the kidney. Urea is formed in the urea 
cycle from NH4
+, CO2, and the nitrogen of aspartate [59, 60]. The cycle occurs mainly 
in the liver. Ammonia travels to the liver from other tissues, mainly in the form of ala-
nine and glutamine and is released from amino acids in the liver by a series of trans-
amination and deamination reactions. Urea cycle enzyme deficiency will result in 
insufficient elimination of NH4 
+ or hyperammonemia which leads to central nervous 
system deterioration in the form of mental retardation, seizure, coma, and death 
[60]. The deamination of amino acids, transamination of most amino acids with 
α-ketoglutaric acid to form glutamic acids, and operation of glutaminase enzyme in 
the kidney represent the main source of ammonia in the human body. In addition 
to these sources of ammonia, this can be produced during purine and pyrimidine 
catabolism, by the action of intestinal bacteria on the non-absorbed dietary amino 
acids, or by the action of monoamine oxidase enzyme. Therefore, ammonia can 
be considered to be an important biomarker monitored in the blood, urine, saliva 
or breath [57–65]. The ammonia concentration is dependent on a range of factors 
including the health status of the patient, the route of sampling (nasal or oral), 
contribution from oral bacteria, diet, pharmaceutical use, physical activity and levels 
of metabolic activity. High levels of ammonia are associated with a variety of patho-
logical conditions, such as hepatic and renal dysfunction, Reye’s syndrome, errors 
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in the metabolism of urea cycle (urea cycle disorders, UCD) and is also a potential 
biomarker in exercise physiology and studies of drug metabolism. Normal concentra-
tion of ammonia in exhaled breath is 50–2000 ppb (parts per billion) [61–66].
3.3.2 Ethylene
Ethylene (C2H4) is produced by the oxidation of cellular lipids [67, 68]. The 
relation among ethylene, free radicals, and diabetes can be explained by the oxida-
tive stress. The free radicals attack cellular biomembranes causing cell damage and 
even cell death [69, 70]. A free radical is an unstable and highly reactive molecular 
species with an unpaired electron that can donate or accept an electron from other 
molecules [71, 72].
There are many types of radicals, but the species highly unstable and concern in 
biological systems are derived from oxygen and known as reactive oxygen species 
(ROS), such as superoxide radicals, O2 
· -, hydrogen peroxide, H2O2, and hydroxyl 
radicals, HO· [70–72]. Under stress, ROS levels increase and this can lead to signifi-
cant cell damage, damage known as oxidative stress. The term “oxidative stress” (OS) 
is defined as the imbalance between the production of free radicals and the body’s 
ability to defend itself [18, 19]. This process is kept in balance by the antioxidant 
defense system. Certain chronic diseases such as atherosclerosis, cancer, diabetes, 
rheumatoid arthritis, post-ischemic perfusion injury, myocardial infarction, car-
diovascular disease, chronic inflammation, stroke and septic shock, aging and other 
degenerative diseases in humans can be caused or their process it can be accelerated 
by the appearance of oxidative lesions at the biomolecular level in (lipids, proteins or 
DNA) when there is an imbalance in the production of free radicals [18, 19, 69–72].
The human body contains a high percentage of lipids (including polyunsatu-
rated fatty acids - PUFA) vulnerable to free radical attack. Lipid peroxidation (LP) 
occurs as a result of oxidative degradation of polyunsaturated fatty acids induced 
by free radicals. Therefore, in LP process a peroxidative sequence is initiated by 
the attack of any free radical species which can extract a hydrogen atom from the 
group of methylene (CH2), together with an electron on the carbon atom (•CH). By 
molecular rearrangement the resulting carbon radical is stabilized and is produce 
a conjugated diene that formed a lipid peroxyl radical (LOO•). But, the propaga-
tion of LP continues because these radicals can still extract hydrogen atoms from 
other lipid molecules to form the lipid hydroperoxides (LOOH). The LP process is 
finished with the end products that includes malondialdehyde, 4-hidroxinonenal 
and hydrocarbons, such as pentane, ethane and ethylene [18, 19, 68–74]. The stable 
end-products of LP, such as ethane, ethylene and pentane are suitable for the 
estimation of cell damage, because these species are excreted in the breath within 
a few minutes of their formation in tissues. Excess ethylene in the exhaled breath 
is associated with biochemical events around LP and can be considered a direct 
measurement of oxidative stress [67–69, 74]. Ethylene was one of the first breath 
compounds studied, being reported to range between 3 and 100 ppb [75, 76].
4.  Laser photoacoustic spectroscopy as a method for breath VOCs 
detection
The analysis of trace gases from human breath for medical monitoring and 
diagnostics and require gas sensors characterized by high sensitivity and selectivity 
(to avoid interference from other potential interfering species), multi-component 
capability, real time measurements, large dynamic range, in situ measurements, 
ease to use. Laser photoacoustic spectroscopy (LPAS) is sufficiently sensitive and 
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rapid to allow the simultaneous analyses of several trace gas metabolites in single 
breath exhalations. Over the years, the LPAS technique has demonstrated its ability 
to detect traces of gas in fields such as biology and medicine due to several factors, 
such as: real-time detection of one or more volatile compounds, detection limits 
ranging from ppm (parts-per-million) to ppb (parts-per-billion), high sensitivity 
and selectivity, use of a single breath collection from a small sampling volume (few 
100 ml) without the need for further preparation [66–68, 75–82].
4.1 Laser photoacoustic spectroscopy: basic principles
Laser photoacoustic spectroscopy is based on the photoacoustic effect that 
occurs at the interaction between light and matter with the generation of a sound 
wave. In 1880, Alexander Graham Bell discovered these phenomena [83] while 
trying to find wireless communication. Thus, he discovered that certain optically 
absorbing solids emit a sound when illuminated by a modulated light. In 1881, 
Bell [84] Tyndall [85], Röntgen [86] and Preece [87] have demonstrated that the 
photoacoustic (PA) effect occurs not only in solid but also in liquid and gas. They 
found also, that the sound was stronger when the sample was placed in a cavity 
called photophone or spectrophone. With the appearance of sensitive microphones, 
increased interest in this technique. Afterwards, techniques based on this phenom-
enon have been known a continuous development, and today can be applied in 
almost all disciplines of Science and Technology.
An instrument based on the PA effect and which uses a laser as a radiation source, 
has important advantages for the analysis of gas traces such as high sensitivity ppb or 
even ppt (parts per trillion) concentrations and selectivity, high dynamic range, high 
accuracy and precision, good time resolution, versatility, reliability, robustness and 
is easy to use.
Over the years, photoacoustic spectroscopy (PAS) has proven its ability to detect 
traces of gas and has been used successfully as a gas sensor in biological and medical 
applications [88–93].
In gases, the PA effect is produced as a result of the following sequences (see 
Figure 1) [76]: absorption of incident laser radiation modulated in frequency or 
amplitude by the target gas molecules; local heating due to non-radiative relaxation; 
the extension and contraction of the gas sample that determines the pressure varia-
tion, which is an acoustic wave; detection of acoustic waves using microphones.
4.2 Experimental section for VOCs breath analysis
Exhaled breath was analyzed using a LPAS system and we have measured 
ammonia and ethylene concentration from the exhaled breath in subjects with 
T2DM and healthy subjects [66, 75, 76]. The block diagram of the laser PA spec-
trometer is presented in Figure 2.
LPAS main components of the system are: a CO2 laser (home-built) emit-
ting in the 9.2–10.8 μm range (area where ammonia and ethylene shows a high 
Figure 1. 
Schematic of the physical processes occurring in PAS [76].
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absorption), frequency-stabilized and an output power between 2 and 5 W, and 
an external PA cell (the external resonator home-build), inside it being mounted 
four microphones (sensitivity of 20 mV/Pa each), connected in series are mounted 
flush with the internal surface of the resonator tube. Before entering into the PA 
cell, the cw laser beam is modulated by a mechanical chopper that operate at the 
resonant frequency of the PA cell (564 Hz) and focused by a ZnSe lens. The laser 
beam power after passing through the PA cell is measured by a radiometer con-
nected to a data acquisition interface module together with a lock-in amplifier. 
The acquisition interface is connected to a computer where all experimental data 
are processed in real-time and stored. The software allows the display of several 
parameters, such the values for the PA voltage, average laser power after chopper, 




V (V)—photoacoustic signal (peak-to-peak value);
α (cm−1 atm−1)—gas absorption coefficient at a given wavelength;
C (Pa cm W−1)—cell constant;
PL (W)—cw laser power before chopper;
SM (V Pa
−1)— microphone responsivity;
c (atm)—concentration or partial pressure of the trace gas.
Another important part of the CO2LPAS system is represented by the gas 
handling system. It has the role to ensure the purity of the PA cell, to introduce 
the sample gas into the PA cell at a controlled flow rate, to pump out the sample 
gas from the PA cell, and to monitor the total and partial pressures of mixture 
gas sample. This several functions can be performed by the gas handling system 
without being necessary any disconnections.
4.3 Breath collection
In breath analysis, depending on the desired result, is required a knowledge and 
understanding of respiratory physics. In the individual, normal, resting breathing is 





6 L, of which 4.8 L is called the vital capacity and the remaining 1.2 liters is called 
the residual volume and remains in the lungs [77–79].
Exhaled breath is an inhomogeneous gas mixture composed of “dead space” 
(roughly 150 milliliters) and the gas part represented by the “alveolar” respiration 
coming from the lungs (about 350 milliliters). Human exhalation contains both 
gas molecules resulting from the exchange of blood, but also compounds from 
the atmosphere. In the process of breath gases collection, there are three basic 
approaches [79, 80]:
1. Dead-space gas collection (or upper airway collection), which is the volume 
of air in the conducting airways where gas exchange cannot take place, where 
no exchange of oxygen or carbon dioxide occurs. There is also an alveolar dead 
space, which is the air in those alveoli that are ventilated but not perfused, 
where gas cannot be exchanged.
2. Alveolar collection (pure alveolar gas is collected), refers at the portion of 
exhaled breath that contain gases that have exchanged with blood. In the lungs 
there is a great flow of blood and the exhaled breath that contains both gas 
molecules resulting from the exchange of blood, but also compounds from the 
atmosphere. More specifically, excluding the dead-space from the analysis are 
excluded the chemicals that originate from the atmosphere. Most respiratory 
tests use this type of test because it contains VOCs resulting from endogenous 
activity and the influence of exogenous VOCs is eliminated.
3. Mixed breath collection means that total breath, dead-space air and alveolar 
gas, is collected.
For the desired results must be taken into account different factors such as the 
type of breath collected, single or multiple exhalation, and the technique used for 
sample analysis.
4.4 Protocols and procedures for breath analysis
Our measurement procedure to determine the concentrations of gases involves 
the following basic steps: cleaning the cell, calibration of the cell or measurement of 
the cell responsivity, and acquiring spectra of ethylene and ammonia [45, 56, 57].
For the measurement and detection of the gases from breath, the laser is kept 
tuned where ethylene and ammonia exhibit the strongest and most characteristic 
peaks. The cleaning of the cell must be carried out by successive washing with 
nitrogen of purity 6,0 (99,9999%) at atmospheric pressure, cleaning performed 
each time the contents of the cell are changed. An adequate degree of cell clearance 
is considered to be obtained if the PA signal measured in the nitrogen atmosphere 
has a rather low level, usually 30 μV. Absorption measurements are performed at 
room temperature, in the range 20° C - 22°C.
Exhaled breath samples are collected in aluminized bags (750 ml aluminum-
coated bags) consisting of: a disposable mouthpiece, a tee-mouthpiece assembly 
(including a plastic tee and a removable one-way flutter valve), a bag with the role 
of collecting “dead air” (the first part of expired breath), while the alveolar air in 
the collection bag and a discard multi-patient collection bags are designed to collect 
multiple. The breath sample can be kept in multi-patient collection bags for up to 
6 hours.
Ammonia is a highly adsorbed compound and the ammonia molecules 
adhere very well to the walls of the PA cell, so that to ensure the quality of each 
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measurement, an intense N2 washing cycle of the PA cell is performed. In this way 
the PA signal measured is due exclusively to the absorption of ammonia or ethylene 
molecules. Before measurements the PA cell is filled with pure nitrogen and the 
background signal detected, and we started from a background signal ~25 μV.
After collecting the breath sample, the gas sample is transferred from the bag 
to the PA cell at a controlled flow rate 36 l h−1 (600 standard cubic centimeters per 
minute (sccm)). Before the PA cell is found a trap filled (with a volume > 100 cm3) 
with KOH (potassium hydroxide) pellets replaced after each measurement, pel-
lets used to retain interfering gases such as carbon dioxide (~4% in exhaled breath 
sample) and water vapor [94].
All of the collected samples were analyzed over a period of three months. To 
remove any residual contaminants, all of these bags were thoroughly cleaned 
by flushing with nitrogen gas (purity 99.9999%) and subsequently evacuated 
for breath sample collection. Following the procedure, the breath samples was 
introduced in the PA cell, the PA cell closed and used for measurements. The 
measurements were performed on the 10P (14) laser line (where ethylene exhibits 
a strong absorption with an absorption coefficient of 30.4 cm−1 atm−1) and 9R (30) 
(where ammonia exhibits a strong absorption with an absorption coefficient of 
57 cm−1 atm−1). In this way the signal measured by microphones in PA cell is quanti-
fied and is proportional to the ethylene and to the ammonia concentrations.
5. VOCs measurement from the exhaled breath in type 2 diabetes
Oxidative damage was quantified by measuring breath ethylene and ammonia 
concentrations using CO2LPAS system. PA detection provides necessary selectiv-
ity for analyzing multicomponent mixtures by the use of line-tunable CO2 lasers. 
Breath samples were collected in special sample bags, aluminized multi-patient 
collection bags from QuinTron (750 mL aluminum-coated bags). All samples 
were given between 09:00 and 11:00 a.m. and analyzed using the CO2LPAS sys-
tem. Measurements of HbA1c and glucose were done using standard procedure. 
The subjects involved in this study are persons diagnosed with T2DM (n = 16), 
recruited from the family doctor, age between 42 and 71 years, body mass index 
BMI = 31.4–35.3, known stable cases of T2DM whose medical therapy had been 
unaltered over the last 12 months, and a healthy control group (n = 9), age between 
29 and 42 years, non-smokers, non-diabetics and body mass index BMI = 19.8–23.4. 
From T2DM subjects, 7 present hypertension and inflammatory syndrome. No 
patients were on supplements with antioxidants. Informed consent was obtained 
from all individuals. The participants with hormonal disorders, benign or malig-
nant disorders, renal failure, central nervous system disorders, and also smokers 
were excluded from the study.
As an observation of the results obtained, it can be seen that the average eth-
ylene of T2DM subjects is higher than the average ethylene healthy subjects (see 
Figure 3). The ethylene values in healthy subjects are normal and in the range 
10.73 ppb and 57.13 ppb, but at the subjects with T2DM the ethylene concentra-
tions range was between 78 ppb and 444 ppb. The differences in exhaled breath 
ammonia concentration are presented in Figure 4, where the mean values of 
breath ethylene concentrations in healthy control group and subjects with T2DM 
are presented. The ammonia values in healthy subjects are normal and in the range 
0.832 ppm and 1.76 ppm, but at the subjects with T2DM the ammonia concentra-
tion range was between 2.74 ppm and 10.16 ppm. Our measurements showed a 
significantly increase of ammonia concentrations in the exhaled breath at diabetic 
subjects compared to healthy subjects.
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For the subjects involved in this study, among the exhaled breath analyses, were 
determined blood analyses such as blood glucose levels and glycated hemoglobin 
HbA1C. Table 1 shows the values of HbA1c and glucose blood tests, as well as the 
values of the respiration results obtained with the CO2LPAS system.
Among subjects with T2DM, 7 have hypertension and inflammatory syndrome. 
In those subjects averages of all analyzes, both blood tests and the breathing are 
Parameters Healthy 
subjects
T2DM T2DM with hypertension and 
inflammatory syndrome
Blood glucose  
(mg dL−1)
83.94 ± 9.2 200.17 ± 44.01 200.17 ± 44.01
HbA1C [%] 4.79 ± 0.52 7.88 ± 0.66 8.21 ± 1.1
CC2H4 [ppb] 24 ± 3.35 238 ± 92 246 ± 59
CNH3 [ppm] 1.296 ± 0.18 3.96 ± 0.85 5.16 ± 1.12
Table 1. 
Mean values for subjects involved with standard deviations (SD).
Figure 3. 
Mean breath ethylene concentrations in healthy subjects and T2DM.
Figure 4. 
Mean breath ammonia concentrations in healthy subjects and T2DM.
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higher in subjects with T2DM who have hypertension and inflammatory syndrome 
compared to those who have no health complications.
Our results show a high difference in the HbA1c mean value of healthy group 
and the and the mean values obtained in subjects with T2DM. These differences 
are presented in Figure 5. In diabetes, impaired detoxification of free radicals 
and this degree of damage can be seen in HbA1c, which is a biomarker of oxida-
tive stress.
6. Discussions
Damage to proteins and lipids due to oxidation has been implicated in the patho-
genesis of type diabetes. Previous studies on oxidative stress are based on invasive 
blood samples analysis, and these studies found significant high level of LP product 
such as malondialdehyde [25, 26, 95, 96]. Through this research, Nour Eldin et al. 
2014 shows that malondialdehyde concentration in blood as LP biomarker was 
elevated in T2DM compared to healthy control group, and that there is an associa-
tion between hyperglycemia and oxidative stress [27].
Diabetes mellitus and hypertension are interrelated diseases, and hypertension 
is about twice as frequent in individuals with diabetes as in those without diabetes. 
Breath ammonia concentrations in subjects with diabetes can be a consequence of 
oxidative stress after ROS attack on proteins, accelerated catabolism of proteins due 
to insulin deprivation and hepatic glucose production [28]. According to Erejuwa, 
2012, ROS are involved in insulin signaling, and goes to development of insulin 
resistance [97]. Therefore, oxidative stress increased insulin resistance and increase 
the free radical’s formation in diabetes, which leads to damage in proteins and 
lipids. Hyperglycemia generates an increased level of free radicals which can lead to 
dysfunctions [98, 99] and increases oxidative damage which cause in development 
of health complications in diabetes, complications associated with inflammation 
[100] or vascular disorders [100, 101].
Some of the subjects with T2DM involved in this study, present complications 
such as hypertension and/or inflammatory syndrome. T2DM is an inflammatory 
disease, and inflammation is caused by insulin resistance correlated with obesity, or 
by hyperglycemia and hyperlipidemia.
Figure 5. 
Mean values of HbA1C in n healthy subjects and T2DM.
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Breath ethylene concentrations in subjects with T2DM was found in higher 
level compared with healthy subjects. Breath ethylene is considered a marker of 
oxidative stress, being an end-product of LP, caused by the attack of free radicals on 
polyunsaturated fatty acids. The damage related to free radical’s action increase and 
a direct measurement of the damage can be achieved by quantitative determination 
of ethylene concentrations.
Ammonia is a biomarker of protein metabolism, and at subjects with T2DM, 
insulin deprivation is associated with an increase in amino acids and by an 
accelerated protein catabolism. Moreover, we found that breath ethylene and 
ammonia concentrations are higher in T2DM subjects that present hyperten-
sion and/or inflammatory syndrome than in those without complications. It 
is known that T2DM lead to complications like kidney failure, heart disease, 
cerebrovascular disease, but there is a lack of information of ammonia level in 
subjects with T2DM and the relationship between ammonia level and diabetes 
complications.
In subjects with T2DM by measuring the percentage of HbA1c, clinicians are 
able to get an overall picture of the average blood sugar levels have been for the 
past 2–3 months. Through our measurements, the diabetics present a high level of 
glycated hemoglobin HbA1c. An increased level of HbA1c reflect a poor metabolic 
control of the patients with diabetes in uncontrolled T2DM [102–106].
The relation between level of ammonia and ethylene in the exhaled breath and 
T2DM could be explained by the inadequate insulin control with disease progres-
sion by development of complications such as oxidative stress, inflammatory 
syndrome, and hypertension. The studies show a relation between hyperglycemia, 
oxidative stress and inflammation coexist in pathological processes but also that 
hyperglycemia and free radicals increase the oxidative stress which will then 
activate the inflammatory processes [97, 107].
Future studies are needed to understand the relationship between them and the 
importance of breath ammonia and ethylene biomarkers.
7. Conclusions
Real-time breath ethylene and ammonia monitoring in subjects with type-2 
diabetes using a CO2LPAS system was realized.
This paper has presented accurate measurement of breath ethylene and ammo-
nia concentrations and the results obtained in comparison with the blood samples 
analysis have demonstrated the suitability of the experimental PA system for trace 
gas detection.
This study shows a high level of oxidative stress in people with diabetes through 
a high level of glycated hemoglobin HbA1c, and high concentrations of ethylene and 
ammonia in respiration.
Our study suggests that sensitive, noninvasive, real-time analysis of oxida-
tive stress, using ethylene and ammonia as breath biomarkers, distinguishes 
healthy subjects from those with type 2 diabetes and controlled by uncontrolled 
diabetes.
The breath analysis may also bring opportunities in molecular monitoring for 
other research fields by using an LPAS system.
Despite these advances, there is a continuing need for miniaturized devices, 
in addition to a precise and easy to use instrument, which should provide a quick 
response, preferably in real time.
Further research is therefore required to expand the applicability of breath 
analysis in clinical diagnosis.
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